John H. Kersey mostly deals with Bone marrow, Internal medicine, Immunology, Transplantation and Leukemia. His Bone marrow study integrates concerns from other disciplines, such as T cell, Complication, Monoclonal antibody and Acute lymphocytic leukemia. His Internal medicine research integrates issues from Gastroenterology and Surgery.
The Immunology study combines topics in areas such as Cancer registry, Endocrinology and Oncology. His Transplantation research is multidisciplinary, incorporating elements of Homologous chromosome, Cyclophosphamide, Hepatosplenomegaly, Andrology and Histocompatibility. The various areas that he examines in his Leukemia study include Cancer research, Progenitor cell, Antigen, Calla and Molecular biology.
John H. Kersey mainly focuses on Immunology, Bone marrow, Leukemia, Internal medicine and Molecular biology. John H. Kersey has researched Immunology in several fields, including Haematopoiesis and Stem cell. His Bone marrow study is concerned with the larger field of Pathology.
His Leukemia research is multidisciplinary, incorporating perspectives in Myeloid, Cancer research and Chromosomal translocation. His research in Internal medicine intersects with topics in Gastroenterology, Surgery and Oncology. His biological study spans a wide range of topics, including Cell culture, Gene rearrangement, Gene, Virology and Monoclonal antibody.
His primary areas of study are Leukemia, Cancer research, Myeloid-Lymphoid Leukemia Protein, Myeloid and Molecular biology. His research on Leukemia concerns the broader Immunology. John H. Kersey combines subjects such as Internal medicine, Disease, Oncology and Historical Article with his study of Immunology.
His Cancer research research is multidisciplinary, relying on both Fms-Like Tyrosine Kinase 3, Gene expression profiling, Fusion gene, Immunophenotyping and Cell cycle. His research investigates the connection between Myeloid and topics such as Bone marrow that intersect with problems in Hematopoietic stem cell and Lineage markers. His Molecular biology research also works with subjects such as
John H. Kersey mostly deals with Cancer research, Leukemia, Myeloid-Lymphoid Leukemia Protein, Myeloid and Haematopoiesis. His Leukemia research includes elements of Molecular biology, Gene rearrangement and Fms-Like Tyrosine Kinase 3. The study incorporates disciplines such as Topoisomerase and DNA repair in addition to Molecular biology.
The Haematopoiesis study which covers Progenitor cell that intersects with Immunology, Gene dosage and Malignant transformation. His Fusion gene study combines topics in areas such as Myeloid leukemia, Bone marrow and Fusion protein. His research integrates issues of CD43 and PAX5 in his study of Bone marrow.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors.
Donald J. Giard;Stuart A. Aaronson;George J. Todaro;Paul Arnstein.
Journal of the National Cancer Institute (1973)
Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival.
John E. Wagner;Juliet N. Barker;Todd E. DeFor;K. Scott Baker.
Successful Bone-Marrow Transplantation for Infantile Malignant Osteopetrosis
Peter F. Coccia;William Krivit;Jaroslav Cervenka;Carlyle Clawson.
The New England Journal of Medicine (1980)
A monoclonal antibody (BA-1) reactive with cells of human B lymphocyte lineage.
C. S. Abramson;J. H. Kersey;Tucker W LeBien.
Journal of Immunology (1981)
P-24: a human leukemia-associated and lymphohemopoietic progenitor cell surface structure identified with monoclonal antibody.
John H. Kersey;Tucker W. Lebien;Candice S. Abramson;Roland Newman.
Journal of Experimental Medicine (1981)
Inhibition of FLT3 in MLL: Validation of a therapeutic target identified by gene expression based classification
Scott A Armstrong;Andrew L Kung;Andrew L Kung;Meghann E Mabon;Lewis B Silverman;Lewis B Silverman.
Cancer Cell (2003)
Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome.
Daniel Weisdorf;Robert Haake;Bruce Blazar;Wesley Miller.
Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia.
John H. Kersey;Daniel Weisdorf;Mark E. Nesbit;Tucker W. LeBien.
The New England Journal of Medicine (1987)
Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease.
Wesley Miller;Patrick Flynn;Jeffrey McCullough;Henry H. Balfour.
Childhood non-Hodgkin's lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2).
James R. Anderson;John F. Wilson;R. Derek T. Jenkin;Anna T. Meadows.
The New England Journal of Medicine (1983)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: